First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

NCT03873883 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: EOS100850
DRUG: Pembrolizumab
DRUG: Chemotherapy

Sponsor

iTeos Therapeutics

Collaborators

[object Object]
[object Object]